Leprosy

Infectious Diseases: Third Edition

Volumn 2, Issue , 2010, Pages 1099-1105

  Britton, Warwick J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84860770646     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-04579-7.00103-9     Document Type: Chapter

References (42)

1. Study Group on chemotherapy of leprosy for control programmes. WHO Technical Report Series No. 675 1982, World Health Organization, WHO, Geneva.
2. Study Group on chemotherapy of leprosy. WHO Technical Report Series No 847 1994, World Health Organization, WHO, Geneva.
3. Global leprosy situation, 2007. Wkly Epidemiol Rec 2007, 82:225-232. World Health Organization.
4. Noordeen S.K. The epidemiology of leprosy. Leprosy 1994, 29-48. Churchill Livingstone, Edinburgh. 2nd ed. R.C. Hastings (Ed.).
5. Britton W.J., Lockwood D.N. Leprosy. Lancet 2004, 363:1209-1219.
6. Scollard D.M., Adams L.B., Gillis T.P., Krahenbuhl J.L., Truman R.W., Williams D.L. The continuing challenges of leprosy. Clin Microbiol Rev 2006, 19:338-381.
7. Spencer J.S., Dockrell H.M., Kim H.J., et al. Identification of specific proteins and peptides in Mycobacterium leprae suitable for the selective diagnosis of leprosy. J Immunol 2005, 175:7930-7938.
8. Alter A., Alcais A., Abel L., Schurr E. Leprosy as a genetic model for susceptibility to common infectious diseases. Hum Genet 2008, 123:227-235.
9. Siddiqui M.R., Clerc P., Bruns G., et al. A major susceptibility locus for leprosy in India maps to chromosome 10p13. Nat Genet 2001, 11:439-441.
10. Shaw M.A., Donaldson I.J., Collins A., et al. Association and linkage of leprosy phenotypes with HLA class II and tumour necrosis factor genes. Genes Immun 2001, 2:196-204.
11. Ustianowski A.P., Lawn S.D., Lockwood D.N. Interactions between HIV infection and leprosy: a paradox. Lancet Infect Dis 2006, 6:350-360.
12. Rees R.J.W., Young D.B. The microbiology of leprosy. Leprosy 1994, 49-86. Churchill Livingstone, Edinburgh. 2nd ed. R.C. Hastings (Ed.).
13. Rambukkana A. Molecular basis for the peripheral nerve predilection of Mycobacterium leprae. Curr Opin Microbiol 2001, 4:21-27.
14. Cole S.T., Eiglmeier K., Parkhill J., et al. Massive gene decay in the leprosy bacillus. Nature 2001, 409:1007-1011.
15. Monot M., Honore N., Garnier T., et al. On the origin of leprosy. Science 2005, 308:1040-1042.
16. Young S.K., Ponnighaus J.M., Jain S., et al. Use of short tandem repeat sequences to study Mycobacterium leprae in leprosy patients in Malawi and India. PLoS Negl Trop Dis 2008, 2:e214.
17. Brennan P.J., Vissa V.D. Genomic evidence for the retention of the essential mycobacterial cell wall in the otherwise defective Mycobacterium leprae. Lepr Rev 2001, 72:415-428.
18. Ridley D.S., Jopling W.H. Classification of leprosy according to immunity. A five group system. Int J Lepr 1966, 34:255-273.
19. Britton W.J. The management of leprosy reversal reactions. Lepr Rev 1998, 69:225-234.
20. Kahawita I.P., Lockwood D.N. Towards understanding the pathology of erythema nodosum leprosum. Trans R Soc Trop Med Hyg 2008, 102:329-337.
21. Saunderson P., Gebre S., Desta K., Byass P., Lockwood D.N. The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome. Lepr Rev 2000, 71:285-308.
22. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996, 348:17-24. Karonga Prevention Trial Group.
23. Setia M.S., Steinmaus C., Ho C.S., Rutherford G.W. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect Dis 2006, 6:162-170.
24. Moet F.J., Pahan D., Oskam L., Richardus J.H. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ 2008, 336:761-764.
25. Pfaltzgraff R.E., Ramu G. Clinical leprosy. Leprosy 1994, Churchill Livingstone, Edinburgh. 2nd ed. R.C. Hastings (Ed.).
26. Walker S.L., Lockwood D.N. The clinical and immunological features of leprosy. Br Med Bull 2006, 77-78:103-121.
27. van Brakel W.H., Nicholls P.G., Wilder-Smith E.P., Das L., Barkataki P., Lockwood D.N. Early diagnosis of neuropathy in leprosy-comparing diagnostic tests in a large prospective study (the INFIR Cohort Study). PLoS Negl Trop Dis 2008, 2:e212.
28. Croft R.P., Nicholls P.G., Steyerberg E.W., Richardus J.H., Cairns W., Smith S. A clinical prediction rule for nerve-function impairment in leprosy patients. Lancet 2000, 355:1603-1606.
29. Richardus J.H., Nicholls P.G., Croft R.P., Withington S.G., Smith W.C. Incidence of acute nerve function impairment and reactions in leprosy: a prospective cohort analysis after 5 years of follow-up. Int J Epidemiol 2004, 33:337-343.
30. van Brakel W.H., Khawas I.B. Silent neuropathy in leprosy: an epidemiological description. Int J Lepr 1994, 65:350-360.
31. Pocaterra L., Jain S., Reddy R., et al. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. Am J Trop Med Hyg 2006, 74:868-879.
32. Joffrion V.C. Ocular leprosy. Leprosy 1994, 353-366. Churchill Livingstone, Edinburgh. 2nd ed. R.C. Hastings (Ed.).
33. Int J Lepr Oth Myco Dis 2002, 70(Suppl):S1-S62. Report of the International Leprosy Association Technical Forum.
34. Honore N., Roche P.W., Grosset J.H., Cole S.T. A method for rapid detection of rifampicin-resistant isolates of Mycobacterium leprae. Lepr Rev 2001, 72:441-448.
35. Williams D.L., Spring L., Harris E., Roche P., Gillis T.P. Dihydropteroate synthase of Mycobacterium leprae and dapsone resistance. Antimicrob Agents Chemother 2000, 44:1530-1537.
36. Expert Committee on Leprosy, 7th Report. WHO Technical Report Series No. 674 1998, World Health Organization, WHO, Geneva.
37. Gupte M.D. Field trials of a single dose of the combination rifampicin-ofloxacin-minocycline (ROM) for the treatment of paucibacillary leprosy. Lepr Rev 2000, 71(Suppl):S77-80.
38. Van Veen N.H., Nicholls P.G., Smith W.C., Richardus J.H. Corticosteroids for treating nerve damage in leprosy. Cochrane Database Syst Rev 2007, (2). CD005491.
39. Croft R.P., Nicholls P.G., Richardus J.H., Smith W.C. The treatment of acute nerve function impairment in leprosy: results from a prospective cohort study in Bangladesh. Lepr Rev 2000, 71:154-168.
40. Walker S.L., Waters M.F., Lockwood D.N. The role of thalidomide in the management of erythema nodosum leprosum. Lepr Rev 2007, 78:197-215.
41. Srinivasin H. Rehabilitation in leprosy. Leprosy 1994, 411-448. Churchill Livingstone, Edinburgh. 2nd ed. R.C. Hastings (Ed.).
42. Nicholls P.G. Guidelines for social and economic rehabilitation. Lepr Rev 2000, 71:422-465.